Roland Utz

This inventor holds 6 USPTO granted patents. Top assignees: Hoechst Aktiengesellschaft, Aventis Pharma Deutschland, Gmbh. Active years: 1990-2005.

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 47(Granted Patents)

Company Filing History:

5 out of 6,705

Hoechst Aktiengesellschaft

patents

1 out of 330

Aventis Pharma Deutschland, Gmbh

patents

Years Active: 1990-2005

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6894184 - Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides (2005-05-17),

2. 5451573 - Substituted cyclohexane derivatives for the treatment of diseases (1995-09-19),

3. 5215990 - Substituted pyrimidine derivatives, a process for the preparation (1993-06-01),

4. 5194442 - 2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical (1993-03-16),

5. 5043344 - Unsaturated N-benzopyranyllactams (1991-08-27),

6. 4943576 - Substituted quinoxalyl-imidazolidine-2,4-diones, processes for their (1990-07-24),

Title: Roland Utz - Innovative Inventor from Messel

Introduction: Roland Utz is a renowned inventor hailing from Messel, Germany, known for his groundbreaking contributions to various industries.

Latest Patents: Roland Utz holds several patents in the fields of renewable energy, sustainable agriculture, and advanced materials.

Career Highlights: With a career spanning over two decades, Roland Utz has worked with leading research institutions and companies to develop cutting-edge technologies that have revolutionized the way we live and work.

Collaborations: Throughout his career, Roland Utz has collaborated with top scientists, engineers, and inventors from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Roland Utz's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor in the global innovation landscape.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]